Dental Patient Care America, Inc.
Dental Patient Care America, Inc. (DPAT) Stock Competitors & Peer Comparison
See (DPAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DPAT | $0.05 | +4.84% | 1.1M | -2.25 | -$0.02 | N/A |
| FSNUY | $12.57 | -1.02% | 113.1B | 21.27 | $0.59 | +2.25% |
| FSNUF | $54.35 | +0.00% | 30.6B | 22.84 | $2.38 | +2.08% |
| JDHIY | $6.85 | +0.00% | 21.9B | 28.54 | $0.24 | N/A |
| JDHIF | $6.15 | +0.00% | 19.7B | 29.29 | $0.21 | N/A |
| FMCQF | $49.21 | +0.00% | 13.7B | 16.97 | $2.90 | +3.30% |
| IHHHF | $1.45 | +0.00% | 12.8B | 20.71 | $0.07 | +1.72% |
| BDULF | $0.66 | +0.00% | 10.5B | 22.00 | $0.03 | +4.79% |
| BDUUF | $0.65 | +0.00% | 10.3B | 21.67 | $0.03 | +4.66% |
| BDUUY | $20.42 | +0.00% | 8.1B | 16.60 | $1.23 | +4.63% |
Stock Comparison
DPAT vs FSNUY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, FSNUY has a market cap of 113.1B. Regarding current trading prices, DPAT is priced at $0.05, while FSNUY trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas FSNUY's P/E ratio is 21.27. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUY's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FSNUY's competition here
DPAT vs FSNUF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, FSNUF has a market cap of 30.6B. Regarding current trading prices, DPAT is priced at $0.05, while FSNUF trades at $54.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas FSNUF's P/E ratio is 22.84. In terms of profitability, DPAT's ROE is +0.45%, compared to FSNUF's ROE of +0.06%. Regarding short-term risk, DPAT and FSNUF have similar daily volatility (0.00).Check FSNUF's competition here
DPAT vs JDHIY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, JDHIY has a market cap of 21.9B. Regarding current trading prices, DPAT is priced at $0.05, while JDHIY trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas JDHIY's P/E ratio is 28.54. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIY's ROE of +0.09%. Regarding short-term risk, DPAT and JDHIY have similar daily volatility (0.00).Check JDHIY's competition here
DPAT vs JDHIF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, JDHIF has a market cap of 19.7B. Regarding current trading prices, DPAT is priced at $0.05, while JDHIF trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas JDHIF's P/E ratio is 29.29. In terms of profitability, DPAT's ROE is +0.45%, compared to JDHIF's ROE of +0.09%. Regarding short-term risk, DPAT and JDHIF have similar daily volatility (0.00).Check JDHIF's competition here
DPAT vs FMCQF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, FMCQF has a market cap of 13.7B. Regarding current trading prices, DPAT is priced at $0.05, while FMCQF trades at $49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas FMCQF's P/E ratio is 16.97. In terms of profitability, DPAT's ROE is +0.45%, compared to FMCQF's ROE of +0.07%. Regarding short-term risk, DPAT and FMCQF have similar daily volatility (0.00).Check FMCQF's competition here
DPAT vs IHHHF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, IHHHF has a market cap of 12.8B. Regarding current trading prices, DPAT is priced at $0.05, while IHHHF trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas IHHHF's P/E ratio is 20.71. In terms of profitability, DPAT's ROE is +0.45%, compared to IHHHF's ROE of +0.07%. Regarding short-term risk, DPAT and IHHHF have similar daily volatility (0.00).Check IHHHF's competition here
DPAT vs BDULF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BDULF has a market cap of 10.5B. Regarding current trading prices, DPAT is priced at $0.05, while BDULF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BDULF's P/E ratio is 22.00. In terms of profitability, DPAT's ROE is +0.45%, compared to BDULF's ROE of +0.15%. Regarding short-term risk, DPAT and BDULF have similar daily volatility (0.00).Check BDULF's competition here
DPAT vs BDUUF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BDUUF has a market cap of 10.3B. Regarding current trading prices, DPAT is priced at $0.05, while BDUUF trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BDUUF's P/E ratio is 21.67. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUF's ROE of +0.15%. Regarding short-term risk, DPAT and BDUUF have similar daily volatility (0.00).Check BDUUF's competition here
DPAT vs BDUUY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BDUUY has a market cap of 8.1B. Regarding current trading prices, DPAT is priced at $0.05, while BDUUY trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BDUUY's P/E ratio is 16.60. In terms of profitability, DPAT's ROE is +0.45%, compared to BDUUY's ROE of +0.15%. Regarding short-term risk, DPAT and BDUUY have similar daily volatility (0.00).Check BDUUY's competition here
DPAT vs RMYHY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RMYHY has a market cap of 6.4B. Regarding current trading prices, DPAT is priced at $0.05, while RMYHY trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RMYHY's P/E ratio is 31.70. In terms of profitability, DPAT's ROE is +0.45%, compared to RMYHY's ROE of +0.06%. Regarding short-term risk, DPAT and RMYHY have similar daily volatility (0.00).Check RMYHY's competition here
DPAT vs RMSYF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RMSYF has a market cap of 5.7B. Regarding current trading prices, DPAT is priced at $0.05, while RMSYF trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RMSYF's P/E ratio is 357.14. In terms of profitability, DPAT's ROE is +0.45%, compared to RMSYF's ROE of +0.06%. Regarding short-term risk, DPAT and RMSYF have similar daily volatility (0.00).Check RMSYF's competition here
DPAT vs BUHPF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BUHPF has a market cap of 4.5B. Regarding current trading prices, DPAT is priced at $0.05, while BUHPF trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BUHPF's P/E ratio is 20.93. In terms of profitability, DPAT's ROE is +0.45%, compared to BUHPF's ROE of +0.26%. Regarding short-term risk, DPAT and BUHPF have similar daily volatility (0.00).Check BUHPF's competition here
DPAT vs MCVEF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MCVEF has a market cap of 4.1B. Regarding current trading prices, DPAT is priced at $0.05, while MCVEF trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MCVEF's P/E ratio is 52.40. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEF's ROE of +0.16%. Regarding short-term risk, DPAT and MCVEF have similar daily volatility (0.00).Check MCVEF's competition here
DPAT vs ANHGY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, DPAT is priced at $0.05, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, DPAT's ROE is +0.45%, compared to ANHGY's ROE of N/A. Regarding short-term risk, DPAT and ANHGY have similar daily volatility (0.00).Check ANHGY's competition here
DPAT vs BUGDF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BUGDF has a market cap of 3.8B. Regarding current trading prices, DPAT is priced at $0.05, while BUGDF trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BUGDF's P/E ratio is 16.96. In terms of profitability, DPAT's ROE is +0.45%, compared to BUGDF's ROE of +0.26%. Regarding short-term risk, DPAT and BUGDF have similar daily volatility (0.00).Check BUGDF's competition here
DPAT vs MCVEY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MCVEY has a market cap of 2.5B. Regarding current trading prices, DPAT is priced at $0.05, while MCVEY trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, DPAT's ROE is +0.45%, compared to MCVEY's ROE of +0.14%. Regarding short-term risk, DPAT and MCVEY have similar daily volatility (0.00).Check MCVEY's competition here
DPAT vs ORPEF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, DPAT is priced at $0.05, while ORPEF trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, DPAT's ROE is +0.45%, compared to ORPEF's ROE of -0.13%. Regarding short-term risk, DPAT and ORPEF have similar daily volatility (0.00).Check ORPEF's competition here
DPAT vs EXETF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, EXETF has a market cap of 1.8B. Regarding current trading prices, DPAT is priced at $0.05, while EXETF trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas EXETF's P/E ratio is 23.11. In terms of profitability, DPAT's ROE is +0.45%, compared to EXETF's ROE of +0.48%. Regarding short-term risk, DPAT is less volatile compared to EXETF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EXETF's competition here
DPAT vs LWSCF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, LWSCF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.05, while LWSCF trades at $15.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas LWSCF's P/E ratio is 43.16. In terms of profitability, DPAT's ROE is +0.45%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to LWSCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LWSCF's competition here
DPAT vs RAFLF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.05, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, DPAT's ROE is +0.45%, compared to RAFLF's ROE of +0.06%. Regarding short-term risk, DPAT and RAFLF have similar daily volatility (0.00).Check RAFLF's competition here
DPAT vs RHCGF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RHCGF has a market cap of 1.4B. Regarding current trading prices, DPAT is priced at $0.05, while RHCGF trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RHCGF's P/E ratio is -5.04. In terms of profitability, DPAT's ROE is +0.45%, compared to RHCGF's ROE of -0.14%. Regarding short-term risk, DPAT and RHCGF have similar daily volatility (0.00).Check RHCGF's competition here
DPAT vs TTALF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, TTALF has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.05, while TTALF trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas TTALF's P/E ratio is 10.53. In terms of profitability, DPAT's ROE is +0.45%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, DPAT and TTALF have similar daily volatility (0.00).Check TTALF's competition here
DPAT vs RKAGY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RKAGY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.05, while RKAGY trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RKAGY's P/E ratio is 24.73. In terms of profitability, DPAT's ROE is +0.45%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, DPAT and RKAGY have similar daily volatility (0.00).Check RKAGY's competition here
DPAT vs RYHTY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RYHTY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.05, while RYHTY trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RYHTY's P/E ratio is -4.02. In terms of profitability, DPAT's ROE is +0.45%, compared to RYHTY's ROE of -0.14%. Regarding short-term risk, DPAT is less volatile compared to RYHTY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RYHTY's competition here
DPAT vs RHKJF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, DPAT is priced at $0.05, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, DPAT's ROE is +0.45%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, DPAT and RHKJF have similar daily volatility (0.00).Check RHKJF's competition here
DPAT vs LTGHF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, LTGHF has a market cap of 978.7M. Regarding current trading prices, DPAT is priced at $0.05, while LTGHF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas LTGHF's P/E ratio is -11.40. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHF's ROE of +8.48%. Regarding short-term risk, DPAT and LTGHF have similar daily volatility (0.00).Check LTGHF's competition here
DPAT vs LTGHY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, LTGHY has a market cap of 955.4M. Regarding current trading prices, DPAT is priced at $0.05, while LTGHY trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas LTGHY's P/E ratio is -10.48. In terms of profitability, DPAT's ROE is +0.45%, compared to LTGHY's ROE of +0.38%. Regarding short-term risk, DPAT is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LTGHY's competition here
DPAT vs NWKHY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NWKHY has a market cap of 854.5M. Regarding current trading prices, DPAT is priced at $0.05, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NWKHY's P/E ratio is 10.39. In terms of profitability, DPAT's ROE is +0.45%, compared to NWKHY's ROE of +0.16%. Regarding short-term risk, DPAT and NWKHY have similar daily volatility (0.00).Check NWKHY's competition here
DPAT vs JXFGF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, JXFGF has a market cap of 782.5M. Regarding current trading prices, DPAT is priced at $0.05, while JXFGF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas JXFGF's P/E ratio is -5.80. In terms of profitability, DPAT's ROE is +0.45%, compared to JXFGF's ROE of -0.11%. Regarding short-term risk, DPAT and JXFGF have similar daily volatility (0.00).Check JXFGF's competition here
DPAT vs WHTCF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, WHTCF has a market cap of 684.6M. Regarding current trading prices, DPAT is priced at $0.05, while WHTCF trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas WHTCF's P/E ratio is -134.00. In terms of profitability, DPAT's ROE is +0.45%, compared to WHTCF's ROE of -0.06%. Regarding short-term risk, DPAT is less volatile compared to WHTCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check WHTCF's competition here
DPAT vs KDGTF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, DPAT is priced at $0.05, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, DPAT's ROE is +0.45%, compared to KDGTF's ROE of N/A. Regarding short-term risk, DPAT and KDGTF have similar daily volatility (0.00).Check KDGTF's competition here
DPAT vs WFHG Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, WFHG has a market cap of 476.9M. Regarding current trading prices, DPAT is priced at $0.05, while WFHG trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas WFHG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WFHG's ROE of +0.00%. Regarding short-term risk, DPAT and WFHG have similar daily volatility (0.00).Check WFHG's competition here
DPAT vs ORRRY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, DPAT is priced at $0.05, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, DPAT and ORRRY have similar daily volatility (0.00).Check ORRRY's competition here
DPAT vs BTMDW Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, DPAT is priced at $0.05, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.45%, compared to BTMDW's ROE of -0.35%. Regarding short-term risk, DPAT is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BTMDW's competition here
DPAT vs MFCSF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MFCSF has a market cap of 218.9M. Regarding current trading prices, DPAT is priced at $0.05, while MFCSF trades at $11.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MFCSF's P/E ratio is 15.05. In terms of profitability, DPAT's ROE is +0.45%, compared to MFCSF's ROE of +0.27%. Regarding short-term risk, DPAT and MFCSF have similar daily volatility (0.00).Check MFCSF's competition here
DPAT vs MKLNF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MKLNF has a market cap of 214.8M. Regarding current trading prices, DPAT is priced at $0.05, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, DPAT's ROE is +0.45%, compared to MKLNF's ROE of +0.16%. Regarding short-term risk, DPAT and MKLNF have similar daily volatility (0.00).Check MKLNF's competition here
DPAT vs CHHHF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, CHHHF has a market cap of 172.7M. Regarding current trading prices, DPAT is priced at $0.05, while CHHHF trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas CHHHF's P/E ratio is 9.17. In terms of profitability, DPAT's ROE is +0.45%, compared to CHHHF's ROE of +0.28%. Regarding short-term risk, DPAT and CHHHF have similar daily volatility (0.00).Check CHHHF's competition here
DPAT vs HWAIF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, HWAIF has a market cap of 164.6M. Regarding current trading prices, DPAT is priced at $0.05, while HWAIF trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas HWAIF's P/E ratio is -5.61. In terms of profitability, DPAT's ROE is +0.45%, compared to HWAIF's ROE of -0.39%. Regarding short-term risk, DPAT is less volatile compared to HWAIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HWAIF's competition here
DPAT vs COLRF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, DPAT is priced at $0.05, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas COLRF's P/E ratio is -8.00. In terms of profitability, DPAT's ROE is +0.45%, compared to COLRF's ROE of +0.00%. Regarding short-term risk, DPAT and COLRF have similar daily volatility (0.00).Check COLRF's competition here
DPAT vs VTIAF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, VTIAF has a market cap of 111.1M. Regarding current trading prices, DPAT is priced at $0.05, while VTIAF trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas VTIAF's P/E ratio is -9.11. In terms of profitability, DPAT's ROE is +0.45%, compared to VTIAF's ROE of -0.71%. Regarding short-term risk, DPAT and VTIAF have similar daily volatility (0.00).Check VTIAF's competition here
DPAT vs TOKIF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, TOKIF has a market cap of 101.4M. Regarding current trading prices, DPAT is priced at $0.05, while TOKIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas TOKIF's P/E ratio is -0.57. In terms of profitability, DPAT's ROE is +0.45%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, DPAT is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TOKIF's competition here
DPAT vs NAFS Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NAFS has a market cap of 59.6M. Regarding current trading prices, DPAT is priced at $0.05, while NAFS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NAFS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NAFS's ROE of +0.31%. Regarding short-term risk, DPAT is less volatile compared to NAFS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NAFS's competition here
DPAT vs MCIOF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, DPAT is priced at $0.05, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, DPAT's ROE is +0.45%, compared to MCIOF's ROE of N/A. Regarding short-term risk, DPAT and MCIOF have similar daily volatility (0.00).Check MCIOF's competition here
DPAT vs ASSF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, DPAT is priced at $0.05, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ASSF's P/E ratio is -33.33. In terms of profitability, DPAT's ROE is +0.45%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, DPAT and ASSF have similar daily volatility (0.00).Check ASSF's competition here
DPAT vs NVLPF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NVLPF has a market cap of 22.4M. Regarding current trading prices, DPAT is priced at $0.05, while NVLPF trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NVLPF's P/E ratio is 25.68. In terms of profitability, DPAT's ROE is +0.45%, compared to NVLPF's ROE of -0.01%. Regarding short-term risk, DPAT and NVLPF have similar daily volatility (0.00).Check NVLPF's competition here
DPAT vs USNU Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, DPAT is priced at $0.05, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas USNU's P/E ratio is -9.41. In terms of profitability, DPAT's ROE is +0.45%, compared to USNU's ROE of -0.71%. Regarding short-term risk, DPAT is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check USNU's competition here
DPAT vs HQDA Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, DPAT is priced at $0.05, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas HQDA's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to HQDA's ROE of -0.06%. Regarding short-term risk, DPAT and HQDA have similar daily volatility (0.00).Check HQDA's competition here
DPAT vs GBCS Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, GBCS has a market cap of 12.9M. Regarding current trading prices, DPAT is priced at $0.05, while GBCS trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas GBCS's P/E ratio is -15.00. In terms of profitability, DPAT's ROE is +0.45%, compared to GBCS's ROE of +0.13%. Regarding short-term risk, DPAT and GBCS have similar daily volatility (0.00).Check GBCS's competition here
DPAT vs EVGRF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, EVGRF has a market cap of 11.9M. Regarding current trading prices, DPAT is priced at $0.05, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas EVGRF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to EVGRF's ROE of +0.22%. Regarding short-term risk, DPAT and EVGRF have similar daily volatility (0.00).Check EVGRF's competition here
DPAT vs HLYK Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, HLYK has a market cap of 10.4M. Regarding current trading prices, DPAT is priced at $0.05, while HLYK trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas HLYK's P/E ratio is -3.05. In terms of profitability, DPAT's ROE is +0.45%, compared to HLYK's ROE of +0.88%. Regarding short-term risk, DPAT is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HLYK's competition here
DPAT vs FPCG Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, DPAT is priced at $0.05, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas FPCG's P/E ratio is 0.09. In terms of profitability, DPAT's ROE is +0.45%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, DPAT and FPCG have similar daily volatility (0.00).Check FPCG's competition here
DPAT vs BICX Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BICX has a market cap of 7.6M. Regarding current trading prices, DPAT is priced at $0.05, while BICX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BICX's P/E ratio is -1.25. In terms of profitability, DPAT's ROE is +0.45%, compared to BICX's ROE of +0.41%. Regarding short-term risk, DPAT and BICX have similar daily volatility (0.00).Check BICX's competition here
DPAT vs RVLWF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RVLWF has a market cap of 5.4M. Regarding current trading prices, DPAT is priced at $0.05, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, DPAT's ROE is +0.45%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, DPAT and RVLWF have similar daily volatility (0.00).Check RVLWF's competition here
DPAT vs VLXC Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, VLXC has a market cap of 3.9M. Regarding current trading prices, DPAT is priced at $0.05, while VLXC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas VLXC's P/E ratio is -4.00. In terms of profitability, DPAT's ROE is +0.45%, compared to VLXC's ROE of +0.74%. Regarding short-term risk, DPAT and VLXC have similar daily volatility (0.00).Check VLXC's competition here
DPAT vs XCRT Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, XCRT has a market cap of 3.9M. Regarding current trading prices, DPAT is priced at $0.05, while XCRT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas XCRT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to XCRT's ROE of +0.26%. Regarding short-term risk, DPAT is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check XCRT's competition here
DPAT vs RHEP Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, RHEP has a market cap of 3M. Regarding current trading prices, DPAT is priced at $0.05, while RHEP trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas RHEP's P/E ratio is -7.71. In terms of profitability, DPAT's ROE is +0.45%, compared to RHEP's ROE of -0.04%. Regarding short-term risk, DPAT is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHEP's competition here
DPAT vs NUMIF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NUMIF has a market cap of 2.9M. Regarding current trading prices, DPAT is priced at $0.05, while NUMIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NUMIF's P/E ratio is -0.30. In terms of profitability, DPAT's ROE is +0.45%, compared to NUMIF's ROE of +11.51%. Regarding short-term risk, DPAT is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NUMIF's competition here
DPAT vs EPWCF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, DPAT is priced at $0.05, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EPWCF's competition here
DPAT vs NRPR Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NRPR has a market cap of 2.1M. Regarding current trading prices, DPAT is priced at $0.05, while NRPR trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NRPR's P/E ratio is -0.03. In terms of profitability, DPAT's ROE is +0.45%, compared to NRPR's ROE of N/A. Regarding short-term risk, DPAT and NRPR have similar daily volatility (0.00).Check NRPR's competition here
DPAT vs GRST Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, GRST has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.05, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas GRST's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to GRST's ROE of +0.17%. Regarding short-term risk, DPAT and GRST have similar daily volatility (0.00).Check GRST's competition here
DPAT vs KJFI Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, KJFI has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.05, while KJFI trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas KJFI's P/E ratio is -0.06. In terms of profitability, DPAT's ROE is +0.45%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, DPAT and KJFI have similar daily volatility (0.00).Check KJFI's competition here
DPAT vs SMAS Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.05, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas SMAS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SMAS's ROE of N/A. Regarding short-term risk, DPAT and SMAS have similar daily volatility (0.00).Check SMAS's competition here
DPAT vs MDGP Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.05, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MDGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, DPAT and MDGP have similar daily volatility (0.00).Check MDGP's competition here
DPAT vs MAHN Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MAHN has a market cap of 1.3M. Regarding current trading prices, DPAT is priced at $0.05, while MAHN trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MAHN's P/E ratio is 55.00. In terms of profitability, DPAT's ROE is +0.45%, compared to MAHN's ROE of N/A. Regarding short-term risk, DPAT and MAHN have similar daily volatility (0.00).Check MAHN's competition here
DPAT vs NOVC Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, DPAT is priced at $0.05, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NOVC's P/E ratio is -0.20. In terms of profitability, DPAT's ROE is +0.45%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, DPAT and NOVC have similar daily volatility (0.00).Check NOVC's competition here
DPAT vs JRSS Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, JRSS has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.05, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas JRSS's P/E ratio is -0.13. In terms of profitability, DPAT's ROE is +0.45%, compared to JRSS's ROE of +0.89%. Regarding short-term risk, DPAT and JRSS have similar daily volatility (0.00).Check JRSS's competition here
DPAT vs PHMB Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.05, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas PHMB's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PHMB's ROE of N/A. Regarding short-term risk, DPAT and PHMB have similar daily volatility (0.00).Check PHMB's competition here
DPAT vs GNOW Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, DPAT is priced at $0.05, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas GNOW's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GNOW's ROE of -12.49%. Regarding short-term risk, DPAT and GNOW have similar daily volatility (0.00).Check GNOW's competition here
DPAT vs MSITF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, DPAT is priced at $0.05, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MSITF's P/E ratio is -0.10. In terms of profitability, DPAT's ROE is +0.45%, compared to MSITF's ROE of N/A. Regarding short-term risk, DPAT and MSITF have similar daily volatility (0.00).Check MSITF's competition here
DPAT vs ARPC Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, DPAT is priced at $0.05, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ARPC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, DPAT and ARPC have similar daily volatility (0.00).Check ARPC's competition here
DPAT vs NXGT Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NXGT has a market cap of 292.2K. Regarding current trading prices, DPAT is priced at $0.05, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NXGT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NXGT's ROE of +0.04%. Regarding short-term risk, DPAT and NXGT have similar daily volatility (0.00).Check NXGT's competition here
DPAT vs BNYN Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, DPAT is priced at $0.05, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BNYN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, DPAT and BNYN have similar daily volatility (0.00).Check BNYN's competition here
DPAT vs FCHS Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, FCHS has a market cap of 131.8K. Regarding current trading prices, DPAT is priced at $0.05, while FCHS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas FCHS's P/E ratio is -0.04. In terms of profitability, DPAT's ROE is +0.45%, compared to FCHS's ROE of +0.20%. Regarding short-term risk, DPAT and FCHS have similar daily volatility (0.00).Check FCHS's competition here
DPAT vs TPIA Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, DPAT is priced at $0.05, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas TPIA's P/E ratio is -0.15. In terms of profitability, DPAT's ROE is +0.45%, compared to TPIA's ROE of +0.55%. Regarding short-term risk, DPAT is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TPIA's competition here
DPAT vs SETO Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, SETO has a market cap of 112.3K. Regarding current trading prices, DPAT is priced at $0.05, while SETO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas SETO's P/E ratio is -0.90. In terms of profitability, DPAT's ROE is +0.45%, compared to SETO's ROE of -123.80%. Regarding short-term risk, DPAT and SETO have similar daily volatility (0.00).Check SETO's competition here
DPAT vs AMBD Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, DPAT is priced at $0.05, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas AMBD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, DPAT and AMBD have similar daily volatility (0.00).Check AMBD's competition here
DPAT vs JNHMF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, JNHMF has a market cap of 69.7K. Regarding current trading prices, DPAT is priced at $0.05, while JNHMF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas JNHMF's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to JNHMF's ROE of -3.60%. Regarding short-term risk, DPAT is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JNHMF's competition here
DPAT vs NMHLY Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, DPAT is priced at $0.05, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, DPAT's ROE is +0.45%, compared to NMHLY's ROE of N/A. Regarding short-term risk, DPAT and NMHLY have similar daily volatility (0.00).Check NMHLY's competition here
DPAT vs CLRD Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, CLRD has a market cap of 28.8K. Regarding current trading prices, DPAT is priced at $0.05, while CLRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas CLRD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, DPAT and CLRD have similar daily volatility (0.00).Check CLRD's competition here
DPAT vs MSGP Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, MSGP has a market cap of 26K. Regarding current trading prices, DPAT is priced at $0.05, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas MSGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, DPAT and MSGP have similar daily volatility (0.00).Check MSGP's competition here
DPAT vs DRWN Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, DRWN has a market cap of 24K. Regarding current trading prices, DPAT is priced at $0.05, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas DRWN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, DPAT and DRWN have similar daily volatility (0.00).Check DRWN's competition here
DPAT vs HSMD Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, HSMD has a market cap of 18.4K. Regarding current trading prices, DPAT is priced at $0.05, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas HSMD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, DPAT and HSMD have similar daily volatility (0.00).Check HSMD's competition here
DPAT vs SCAL Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, DPAT is priced at $0.05, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas SCAL's P/E ratio is 0.04. In terms of profitability, DPAT's ROE is +0.45%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, DPAT and SCAL have similar daily volatility (0.00).Check SCAL's competition here
DPAT vs CEVE Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, CEVE has a market cap of 17.1K. Regarding current trading prices, DPAT is priced at $0.05, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas CEVE's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, DPAT and CEVE have similar daily volatility (0.00).Check CEVE's competition here
DPAT vs PRMD Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, PRMD has a market cap of 12.9K. Regarding current trading prices, DPAT is priced at $0.05, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas PRMD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, DPAT and PRMD have similar daily volatility (0.00).Check PRMD's competition here
DPAT vs GENN Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, DPAT is priced at $0.05, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas GENN's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to GENN's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GENN's competition here
DPAT vs CHCR Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, DPAT is priced at $0.05, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas CHCR's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.45%, compared to CHCR's ROE of N/A. Regarding short-term risk, DPAT and CHCR have similar daily volatility (0.00).Check CHCR's competition here
DPAT vs ACGI Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, DPAT is priced at $0.05, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ACGI's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ACGI's competition here
DPAT vs WEQL Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, WEQL has a market cap of 7.2K. Regarding current trading prices, DPAT is priced at $0.05, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas WEQL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, DPAT and WEQL have similar daily volatility (0.00).Check WEQL's competition here
DPAT vs PAOG Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, PAOG has a market cap of 5K. Regarding current trading prices, DPAT is priced at $0.05, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas PAOG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PAOG's ROE of -0.20%. Regarding short-term risk, DPAT is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PAOG's competition here
DPAT vs SLHGF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, SLHGF has a market cap of 4K. Regarding current trading prices, DPAT is priced at $0.05, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas SLHGF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHGF's ROE of -0.42%. Regarding short-term risk, DPAT and SLHGF have similar daily volatility (0.00).Check SLHGF's competition here
DPAT vs SLHPF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.05, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas SLHPF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to SLHPF's ROE of -0.42%. Regarding short-term risk, DPAT and SLHPF have similar daily volatility (0.00).Check SLHPF's competition here
DPAT vs ERUC Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, ERUC has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.05, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas ERUC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to ERUC's ROE of N/A. Regarding short-term risk, DPAT and ERUC have similar daily volatility (0.00).Check ERUC's competition here
DPAT vs BBAL Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, DPAT is priced at $0.05, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BBAL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, DPAT and BBAL have similar daily volatility (0.00).Check BBAL's competition here
DPAT vs NMMCF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, DPAT is priced at $0.05, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas NMMCF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to NMMCF's ROE of +0.21%. Regarding short-term risk, DPAT is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check NMMCF's competition here
DPAT vs PPRG Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.05, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas PPRG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, DPAT and PPRG have similar daily volatility (0.00).Check PPRG's competition here
DPAT vs KONEF Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, KONEF has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.05, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas KONEF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, DPAT and KONEF have similar daily volatility (0.00).Check KONEF's competition here
DPAT vs OHAQ Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, DPAT is priced at $0.05, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, DPAT's ROE is +0.45%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, DPAT and OHAQ have similar daily volatility (0.00).Check OHAQ's competition here
DPAT vs BNKL Comparison April 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.1M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.05, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -2.25, whereas BNKL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.45%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, DPAT and BNKL have similar daily volatility (0.00).Check BNKL's competition here